Recent ZVSA News
- ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 • GlobeNewswire Inc. • 07/25/2024 11:57:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 01:35:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 01:35:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 01:35:09 AM
- ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model • GlobeNewswire Inc. • 07/18/2024 03:18:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/17/2024 04:15:10 AM
- ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024 • GlobeNewswire Inc. • 07/09/2024 11:57:00 AM
- ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/15/2024 12:35:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 12:30:41 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 05/15/2024 12:25:42 PM
- ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention • GlobeNewswire Inc. • 05/14/2024 11:57:00 AM
- ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease • GlobeNewswire Inc. • 04/29/2024 11:57:00 AM
- ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes • GlobeNewswire Inc. • 04/04/2024 11:57:00 AM
- ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/25/2024 12:17:28 PM
- ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease • GlobeNewswire Inc. • 03/18/2024 11:57:00 AM
- ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024 • GlobeNewswire Inc. • 03/14/2024 11:57:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:25 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/08/2024 10:00:16 PM
- ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity • GlobeNewswire Inc. • 02/29/2024 12:57:00 PM
- ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications • GlobeNewswire Inc. • 02/28/2024 12:57:00 PM
- ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option • GlobeNewswire Inc. • 02/22/2024 12:47:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/14/2024 09:34:51 PM
- ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases • GlobeNewswire Inc. • 02/14/2024 12:53:00 PM
- ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones • GlobeNewswire Inc. • 02/07/2024 01:02:00 PM
- ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes • GlobeNewswire Inc. • 01/31/2024 12:57:00 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM